You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛上調諾誠健華-B(09969.HK)目標價至21元 評級「買入」
阿思達克 03-30 14:01
高盛發表研究報告指,諾誠健華-B(09969.HK)去年下半年錄虧損5,700萬元人民幣,主要來自研發費用按年增長45%及營銷及一般行政費用增長104%,但虧損已較2019年同期的2.43億元人民幣大幅減少。

該行指,諾誠健華在研的BTK抑制劑奧布替尼(Orelabrutinib)今年首季商業化進度理想,正計劃將銷售團隊擴充至200人,今年內覆蓋內地900家醫院。

另外,高盛認為今年下半年潛在的國家醫保藥品目錄談判或為諾誠健華今年的增長動力之一,參考市場上其他BTK抑制劑Brukinsa及Imbruvica定價,認為對BTK抑制劑市場價格有支持作用。

高盛對諾誠健華予以「買入」評級,以反映2月份配股所得資金,以及公司將於今明兩年加大研發投入,但預期今年及明年淨虧損5.85億及3.01億元人民幣,目標價上調至21元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account